WF60.F MindBio Therapeutics Corp.

Healthcare Biotechnology Frankfurt Exchange
0.0635 EUR
Close of Nov 12, 2026
0.0515 2.07
Market cap
EUR 615K
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Mar 2026.

Is WF60.F undervalued?

Graham number

The Graham number of MindBio Therapeutics Corp. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MindBio Therapeutics Corp. fundamental analysis

No fundamental analysis for MindBio Therapeutics Corp. yet.

MindBio Therapeutics Corp. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MindBio Therapeutics Corp.

MindBio Therapeutics Corp., together with its subsidiaries, research, develops, and tests psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for debilitating health conditions, such as de…

Full company profile